Table 1 Patient demographics and characteristics (Cohort 1).

From: A real-world study assessing the impact of retinal fluid on visual acuity outcomes in patients with neovascular age-related macular degeneration in Korea

Baseline characteristics

N = 600

Demographics

Age (years)

Mean (SD)

73.33 (8.88)

Sex, n (%)

Male

347 (57.83)

Clinical characteristics (study eye)

CNV lesion location, n (%)

Extrafoveal

48 (8.00)

Juxtafoveal

145 (24.17)

Subfoveal

407 (67.83)

Total lesion size, n (%)

 ≤ 1 DA

204 (34.00)

1–4 DA

330 (55.00)

 > 4 DA

63 (10.50)

CNV lesion composition, n (%)

Predominantly classic

162 (27.00)

Minimally classic

61 (10.17)

Occult

372 (62.00)

PCV, n (%)

Yes

170 (28.33)

No

387 (64.50)

Un-assessable

43 (7.17)

RAP, n (%)

Yes

57 (9.50)

No

502 (83.67)

Un-assessable

41 (6.83)

Index anti-VEGF therapy, n (%)*

Ranibizumab

211 (35.16)

Bevacizumab

104 (17.34)

Aflibercept

285 (47.5)

  1. CNV, choroidal neovascularization; DA, disc area; n, number of patients; N, total number of patients; PCV, polypoidal choroidal vasculopathy; RAP, retinal angiomatous proliferation; SD, standard deviation.
  2. *Index anti-VEGF, anti-VEGF injection taken during the first/baseline visit.
Back to article page